Prognostic impact of circulating HER2 extracellular domain (ECD) in women with metastatic breast cancer.

被引：0
|
作者：
Zheng, Yabing [1 ]
Shao, Xiying [1 ]
Wang, Xiaojia [1 ]
Shi, Lei [1 ]
Huang, Yuan [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e22038
引用
收藏
页数：1
相关论文
共 50 条
  • [21] HER2 extracellular domain (ECD): A predictive marker of lapatinib treatment benefit in advanced breast cancer
    Lee, C. K.
    Davies, L.
    Gebski, V.
    Lord, S.
    Di Leo, A.
    Johnston, S.
    Geyer, C., Jr.
    Cameron, D.
    Press, M.
    Ellis, C.
    Simes, J.
    deSouza, P.
    CANCER RESEARCH, 2013, 73
  • [22] Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
    Olson, E. M.
    Flores, L. M.
    Najita, J. S.
    Curley, C.
    Jeong, J.
    Murray, K.
    Savoie, J. J.
    Winer, E. P.
    Krop, I. E.
    CANCER RESEARCH, 2011, 71
  • [23] Serum level of HER2 extra cellular domain (ECD) is a significant prognostic factor for survival in metastatic breast cancer without HER2 overexpression on primary tumor.
    Dinocca, S.
    Blot, E.
    Laberge-Le-Couteulx, S.
    Menard, J.-F.
    Guillemet, C.
    Veyret, C.
    Basuyau, J.-P.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S50 - S50
  • [24] Evaluation of circulating HER2 ECD and EGFR in patients with metastatic breast cancer treated with low aggressive chemotherapy
    Sandri, MT
    Johansson, HA
    Zorzino, L
    Salvatici, M
    Neumann, R
    Colleoni, M
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S94 - S95
  • [25] The extracellular domain of Her2 in serum as a biomarker of breast cancer
    Perrier, Alexandre
    Gligorov, Joseph
    Lefevre, Guillaume
    Boissan, Mathieu
    LABORATORY INVESTIGATION, 2018, 98 (06) : 696 - 707
  • [26] Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer
    Mahdavi, Manijeh
    Keyhanfar, Mehrnaz
    Jafarian, Abbas
    Mohabatkar, Hassan
    Rabbani, Mohammad
    TUMOR BIOLOGY, 2014, 35 (12) : 12049 - 12057
  • [27] Serum HER2 extracellular domain before surgery compared with HER2 in breast cancer
    Zidan, J.
    Mzalbat, R.
    Sharabi, A.
    BREAST, 2015, 24 : S44 - S45
  • [28] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.
    Kong, SY
    Kwon, Y
    Lee, DH
    Lee, JS
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 48S - 48S
  • [30] registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer.
    Tanchiu, E
    Kaufman, PA
    Paik, S
    Ulcickas-Yood, M
    Mayer, M
    Tripathy, D
    Rugo, H
    Brufsky, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 46S - 46S
12345